5
6H), 1.33 – 1.06 (m, 5H); 13C NMR: (101 MHz, CDCl3) δ 158.1,
2.61 (q, J = 10.4 Hz, 1H), 2.40 (dd, J = 18.2, 6.4 Hz, 1H), 2.22
ACCEPTED MANUSCRIPT
145.9, 137.2, 127.6, 116.2, 114.0, 71.5, 70.6, 55.2, 48.6, 45.3,
45.0, 42.8, 38.90, 32.2, 32.1, 26.7, 26.3.; MS (GC-MS)
Calculated m/z for [M] = 312.21, Found m/z for [M] = 312.22; IR
(thin film): 2924, 2851, 1611, 512, 1448, 1302, 1249, 1178,
1110, 1035
(qd, J = 11.2, 6.9 Hz, 1H), 2.12 (ddt, J = 14.5, 10.7, 5.5 Hz, 1H).
13C NMR: (151 MHz, CDCl3) δ 158.1, 140.1, 139.4, 136.7,
128.8, 128.3, 127.6, 126.1, 120.3, 113.9, 77.2, 76.7, 71.28, 70.62,
55.2, 48.6, 45.4, 43.6, 42.6, 39.9.
MS (GC-MS) Calculated m/z = 320.43, Found m/z = 320.20
IR (thin film): 3082, 3060, 3027, 3000, 2932, 2908, 2836, 1652,
1607, 1577, 1511, 1495, 1453, 1441, 1420
4.2.3. 6-benzyl-4-(4-methoxyphenyl)-1,3,3a,4,5,7a-
hexahydroisobenzofuran (3c)
Compound 3c was prepared according to the general procedure
and obtained in a 43% yield as a colorless solid after purification
by column chromatography with silica gel and DCM; 1H NMR:
(600 MHz, CDCl3) δ 7.28 (dd, J = 15.8, 8.4 Hz, 2H), 7.21 (t, J =
7.4 Hz, 1H), 7.17 (d, J = 7.5 Hz, 2H), 7.09 (d, J = 8.6 Hz, 2H),
6.82 (d, J = 8.2 Hz, 2H), 5.64 (s, 1H), 4.10 (t, J = 7.3 Hz, 1H),
3.78 (s, 3H), 3.76 (t, J = 7.4 Hz, 1H), 3.44 (dd, J = 11.6, 7.1 Hz,
1H), 3.40 – 3.20 (m, 3H), 2.82 (td, J = 11.2, 6.3 Hz, 1H), 2.61 (q,
J = 10.4 Hz, 1H), 2.40 (dd, J = 18.2, 6.4 Hz, 1H), 2.22 (qd, J =
4.3. Procedure for Formation of Chiral Anion Pyrylium Salts
(Table 1)
The Brønsted acid (1 equiv.) and 1f (1 equiv.) were added to
a vial and suspended in EtOH. Upon heating to approx. 60 °C
using a heat gun for 5 minutes, all material dissolved and the
solution took on a bright orange color. The crude reaction
mixture was allowed to cool and concentrated upon complete
consumption of the starting material. The crude product was
dissolved in MeOH and shaken with hexanes. After separation,
concentration of the MeOH layer and drying under high vacuum
overnight afforded pure oxopyrilium salts. These compounds are
benchtop stable for several days but should be stored at low
temperatures for extended periods.
11.2, 6.9 Hz, 1H), 2.12 (ddt, J = 14.5, 10.7, 5.5 Hz, 1H); 13
C
NMR: (151 MHz, CDCl3) δ 158.1, 140.1, 139.4, 136.7, 128.8,
128.3, 127.6, 126.1, 120.3, 113.9, 77.2, 76.7, 71.28, 70.62, 55.2,
48.6, 45.4, 43.6, 42.6, 39.9; MS (GC-MS) Calculated m/z =
320.43, Found m/z = 320.20; IR (thin film): 3082, 3060, 3027,
3000, 2932, 2908, 2836, 1652, 1607, 1577, 1511, 1495, 1453,
1441, 1420
4.2.4. 6-methyl-4-(4-methoxyphenyl)-1,3,3a,4,5,7a-
hexahydroisobenzofuran (3d)
4.3.1. 2,4,6-tris(4-methoxyphenyl)pyrylium ((11bR)-4-oxido-
2,6-diphenyldinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yl)((trifluoromethyl)sulfonyl)amide (1a)
Compound 3d was prepared according to the general procedure
and obtained in a 10% yield as a colorless solid after purification
by column chromatography with silica gel and DCM; 1H NMR:
(600 MHz, CDCl3) δ 7.16 – 7.11 (m, 2H), 6.85 (d, J = 8.6 Hz,
2H), 5.56 (s, 1H), 4.08 (t, J = 7.2 Hz, 1H), 3.79 (s, 3H), 3.76 (t, J
= 7.4 Hz, 1H), 3.41 (dd, J = 11.6, 7.0 Hz, 1H), 3.31 (dd, J = 11.2,
7.7 Hz, 1H), 2.85 (td, J = 11.2, 6.3 Hz, 1H), 2.56 (d, J = 9.9 Hz,
1H), 2.40 (dd, J = 18.1, 6.5 Hz, 1H), 2.19 (m, 2H), 1.70 (s,
3H);13C NMR: (151 MHz, CDCl3) δ 158.1, 137.0, 136.8, 127.7,
118.8, 114.0, 71.4, 70.7, 55.2, 48.6, 45.5, 42.7, 41.9, 22.9; MS
(GC-MS) Calculated m/z = 244.15, Found m/z = 244.20; IR (thin
film): 3082, 3060, 3027, 3000, 2932, 2908, 2836, 1652, 1607,
1577, 1511, 1495, 1453, 1441, 1420
Compound 1a was prepared according to the general procedure
and obtained in a 74% yield as an orange solid after extraction.;
1H NMR: (600 MHz, CDCl3) δ 8.03 – 7.72 (m, 14H), 7.49 – 7.38
(m, 2H), 7.32 (dd, J = 28.8, 8.5 Hz, 2H), 7.24 (t, J = 7.7 Hz, 4H),
7.09 (d, J = 3.7 Hz, 4H), 6.77 (d, J = 8.5 Hz, 4H), 6.33 (d, J = 8.4
Hz, 2H); 13C NMR: (151 MHz, CDCl3) δ 166.8, 165.4, 164.6,
161.4, 138.0, 137.0, 134.7, 134.1, 132.4, 132.2, 131.2, 131.1,
131.0, 130.4, 130.3, 130.0, 130.0, 128.3, 128.2, 127.7, 127.1,
127.0, 127.0, 126.9, 126.2, 125.9, 125.2, 125.2, 123.4, 120.3,
115.3, 115.2, 109.8, 55.6, 55.2; MS (ESI) Calculated m/z for [M-
H] = 862.21, Found m/z for [M-H] = 863.21778, Calculated m/z
for [M+] = 399.16, Found m/z for [M+] = 399.15859; IR (thin
film): 3432, 2077, 1631, 1606, 1589, 1512, 1484, 1438, 1306,
1261, 1243, 1178, 1096
4.2.5. 6-isopropyl-4-(4-methoxyphenyl)-2-tosyl-
2,3,3a,4,5,7a-hexahydro-1H-isoindole (3e)
Compound 3e was prepared according to the general procedure
and obtained in a 42% yield as a colorless solid after purification
by column chromatography with silica gel and DCM; 1H NMR:
(600 MHz, CDCl3) δ 7.72 – 7.68 (m, 2H), 7.33 (d, J = 7.9 Hz,
2H), 7.09 – 7.05 (m, 2H), 6.90 – 6.85 (m, 2H), 5.47 (s, 1H), 3.83
(s, 3H), 3.70 (dd, J = 9.1, 7.3 Hz, 1H), 3.33 (dd, J = 9.5, 6.8 Hz,
1H), 2.94 (dd, J = 11.8, 9.1 Hz, 1H), 2.75 (dd, J = 11.3, 9.5 Hz,
1H), 2.68 (td, J = 11.2, 6.2 Hz, 1H), 2.46 (s, 1H), 2.37 (ddt, J =
17.9, 6.2, 1.8 Hz, 1H), 2.30 – 2.22 (m, 1H), 2.17 (p, J = 6.9 Hz,
1H), 2.13 – 2.05 (m, 1H), 1.92 (qd, J = 11.3, 6.8 Hz, 1H), 0.99
(dd, J = 6.9, 3.8 Hz, 6H); 13C NMR: (151 MHz, CDCl3) δ 158.3,
146.7, 143.1, 136.0, 129.6, 127.6, 127.2, 116.1, 114.1, 55.2, 52.3,
51.3, 47.3, 43.8, 43.1, 37.3, 34.4, 21.5, 21.5, 21.3; MS (ESI)
Calculated m/z for [M+H] = 426.2103, Found m/z for [M+H] =
426.2082
4.3.2. 2,4,6-tris(4-methoxyphenyl)pyrylium ((11bR)-4-oxido-
2,6-bis(triphenylsilyl)dinaphtho[2,1-d:1',2'
f][1,3,2]dioxaphosphepin-4-yl)((trifluoromethyl)sulfonyl)amide
(1b)
Compound 1b was prepared according to the general procedure
and obtained in a 83% yield as an orange solid after extraction.;
1H NMR: (600 MHz, CDCl3) δ 8.27 (d, J = 9.0 Hz, 4H), 8.16 (s,
2H), 8.13 (d, J = 8.6 Hz, 2H), 7.97 (s, 2H), 7.69 (d, J = 8.3 Hz,
2H), 7.64 – 7.52 (m, 12H), 7.33 (d, J = 8.5 Hz, 2H), 7.29 (t, J =
7.5 Hz, 2H), 7.22 (t, J = 7.7 Hz, 2H), 7.01 (d, J = 7.8 Hz, 18H),
6.91 (d, J = 8.7 Hz, 4H), 6.48 (d, J = 8.4 Hz, 2H), 3.67 (s, 6H),
3.33 (s, 3H); 13C NMR: (151 MHz, CDCl3) δ 167.0, 165.3, 164.5,
161.9, 141.0, 136.9, 135.4, 134.4, 133.6, 130.7, 129.8, 128.5,
128.5, 127.1, 126.9, 126.3, 124.1, 123.9, 122.4, 121.5, 115.3,
115.1, 111.4, 77.2, 77.0, 76.7, 55.7, 55.5; MS (LTQ FT-ICR MS)
Calculated m/z for [M-] = 862.21, Found m/z for [M-] =
863.21778, Calculated m/z for [M+] = 399.16, Found m/z for
[M+] = 399.15862; IR (thin film): 3428, 3069, 3049, 2937, 2041,
1628, 1604, 1512, 1486, 1438, 1408, 1262, 1244, 1178, 1104
4.3.3. 2,4,6-tris(4-methoxyphenyl)pyrylium ((11bR)-4-oxido-
2,6-bis(triphenylsilyl)-8,9,10,11,12,13,14,15-
4.2.2. 5-ethyl-6-(4-methoxyphenyl)bicyclo[2.2.1]hept-2-ene (4b)
Compound 4b was prepared according to the general procedure
and obtained in a 43% yield as a colorless solid after purification
by column chromatography with silica gel and DCM.
1H NMR: (600 MHz, CDCl3) δ 7.28 (dd, J = 15.8, 8.4 Hz, 2H),
7.21 (t, J = 7.4 Hz, 1H), 7.17 (d, J = 7.5 Hz, 2H), 7.09 (d, J = 8.6
Hz, 2H), 6.82 (d, J = 8.2 Hz, 2H), 5.64 (s, 1H), 4.10 (t, J = 7.3
Hz, 1H), 3.78 (s, 3H), 3.76 (t, J = 7.4 Hz, 1H), 3.44 (dd, J = 11.6,
7.1 Hz, 1H), 3.40 – 3.20 (m, 3H), 2.82 (td, J = 11.2, 6.3 Hz, 1H),
octahydrodinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-
yl)((trifluoromethyl)sulfonyl)amide (1c)